A novel programme to evaluate and communicate 10-year risk of CHD reduces predicted risk and improves patients' modifiable risk factor profile by Benner, J S et al.
A novel programme to evaluate and communicate
10-year risk of CHD reduces predicted risk
and improves patients’ modiﬁable risk factor proﬁle
J. S. Benner,
1 L. Erhardt,
2 M. Flammer,
3 R. A. Moller,
3 N. Rajicic,
3 K. Changela,
3 C. Yunis,
3
S. B. Cherry,
1 Z. Gaciong,
4 E. S. Johnson,
5 M. C. J. M. Sturkenboom,
6 J. Garcı´a-Puig,
7 X. Girerd
8,
on behalf of the REACH OUT Investigators*
Introduction
Coronary heart disease (CHD) is the most prevalent
form of cardiovascular disease (CVD) and the most
common cause of death worldwide (1). Hyperten-
sion, dyslipidaemia and cigarette smoking are the
three modiﬁable risk factors most strongly and inde-
pendently associated with CHD (2,3). Pharmacologic
and lifestyle interventions targeting these risk factors
have been shown in large clinical trials and meta-
analyses to reduce the risk of CHD death (4–8).
However, despite the proven beneﬁts of such inter-
ventions, improvements in modiﬁable risk factors
remain suboptimal in clinical practice (9–14). Poten-
tial reasons for this treatment gap are lack of physi-
cian implementation of guidelines and poor patient
adherence to recommended drug therapies or life-
style modiﬁcations (14–18). In particular, despite
advances in therapies in recent years, improvements
in lifestyle factors among patients at risk for CVD
have been minimal (14). Novel strategies for CVD
prevention are urgently required to help motivate
patients and physicians towards improving the
reductions in modiﬁable risk factors achieved in clin-
ical practice, and thus lower patients’ overall risk of
CHD.
Evidence-based guidelines, such as those from the
Fourth Joint Task Force of European and Other
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SUMMARY
Aims: We assessed whether a novel programme to evaluate⁄communicate pre-
dicted coronary heart disease (CHD) risk could lower patients’ predicted Framing-
ham CHD risk vs. usual care. Methods: The Risk Evaluation and Communication
Health Outcomes and Utilization Trial was a prospective, controlled, cluster-rando-
mised trial in nine European countries, among patients at moderate cardiovascular
risk. Following baseline assessments, physicians in the intervention group calcu-
lated patients’ predicted CHD risk and were instructed to advise patients according
to a risk evaluation⁄communication programme. Usual care physicians did not cal-
culate patients’ risk and provided usual care only. The primary end-point was Fra-
mingham 10-year CHD risk at 6 months with intervention vs. usual care. Results:
Of 1103 patients across 100 sites, 524 patients receiving intervention, and 461
receiving usual care, were analysed for efﬁcacy. After 6 months, mean predicted
risks were 12.5% with intervention, and 13.7% with usual care [odds
ratio = 0.896; p = 0.001, adjusted for risk at baseline (17.2% intervention;
16.9% usual care) and other covariates]. The proportion of patients achieving both
blood pressure and low-density lipoprotein cholesterol targets was signiﬁcantly
higher with intervention (25.4%) than usual care (14.1%; p < 0.001), and 29.3%
of smokers in the intervention group quit smoking vs. 21.4% of those receiving
usual care (p = 0.04). Conclusions: A physician-implemented CHD risk evalua-
tion⁄communication programme improved patients’ modiﬁable risk factor proﬁle,
and lowered predicted CHD risk compared with usual care. By combining this strat-
egy with more intensive treatment to reduce residual modiﬁable risk, we believe
that substantial improvements in cardiovascular disease prevention could be
achieved in clinical practice.
What’s known
Guidelines for CVD prevention generally recommend
the assessment and management of overall
cardiovascular risk. However, recommendations are
not consistently implemented by many doctors, and
patients frequently do not meet therapeutic targets
for modiﬁable risk factors such as blood pressure
and lipids. Novel strategies are urgently required to
help improve reductions in modiﬁable risk factors
achieved by patients in clinical practice, and thus
lower their overall risk of CHD.
What’s new
A novel risk evaluation ⁄ communication programme
incorporating the concept of global predicted risk
was associated with greater reductions in 10-year
predicted risk, higher levels of blood pressure and
lipid goal attainment, and an increase in smoking
cessation, compared with usual care. This risk
evaluation ⁄communication strategy could mediate
improvements in CVD prevention in clinical practice,
although to achieve substantial beneﬁts it needs to
be combined with more intensive medical treatment
for multiple risk factors.
doi: 10.1111/j.1742-1241.2008.01872.x
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Clinical Practice (19) and the National Cholesterol
Education Program (NCEP) Adult Treatment Panel
(ATP) III (20), have emphasised the importance of
considering overall cardiovascular risk in CVD man-
agement. Frequently, usual care in clinical practice
involves the treatment of individual risk factors to
target levels, however, a more global approach is
needed to effectively lower patients’ overall risk (18).
Global risk equations, including the Framingham
(21), Prospective Cardiovascular Munster (22) and
Systematic COronary Risk Evaluation (23) models,
can estimate overall CVD⁄CHD risk based on a
patient’s age, sex, blood pressure, cholesterol, smok-
ing status and other cardiovascular risk factors.
While some previous studies have investigated the
beneﬁts of assessing and communicating patients’
predicted CVD⁄CHD risk for improving risk factor
management, these interventions have had limited
beneﬁts (24–26).
Recently, the large EuroAction trial evaluated the
efﬁcacy of a nurse-led, multidimensional approach
that aimed to educate and support coronary patients
and those at risk for CVD to comply with guideline-
recommended treatments and lifestyle changes. Com-
pared with patients receiving usual care, patients
receiving this intervention showed signiﬁcant
improvements in cardiovascular risk factors and com-
pliance with lifestyle changes (27–29). Several other
studies evaluating strategies designed to educate or
motivate physicians and patients have reported posi-
tive changes in patient behaviour and efﬁcacy out-
comes as a result of similar interventions (30–37).
We developed a novel CHD risk evaluation and
communication programme that aimed to incorporate
the concept of global predicted risk into a comprehen-
sive intervention strategy designed both to facilitate
clinical decision making by physicians and to educate
and motivate patients to reduce their global cardiovas-
cular risk. This intervention programme utilises the
Framingham risk calculation for the assessment of 10-
year CHD risk. Although the Framingham model is
not intended to assess treatment effects, we believe
that this can provide a useful tool to communicate a
patient’s global risk, and that relative changes in pre-
dicted Framingham 10-year risk following interven-
tion can provide an indication of the potential
achievable beneﬁts if improvements are maintained
over the long term. The Risk Evaluation And Commu-
nication Health Outcomes and Utilization Trial
(REACH OUT) was therefore conducted to evaluate
the clinical utility of our CHD risk evaluation⁄com-
munication programme for lowering CHD risk as
measured by Framingham risk equations, in compari-
son with usual care, in a multi-country setting (38).
Methods
Study design
The REACH OUT study was a 6-month, parallel
group, prospective, controlled, cluster-randomised,
multinational trial conducted between September
2005 and November 2006. The study design has been
described in more detail in a previous publication
(38). Brieﬂy, study sites in nine European countries
(Czech Republic, Denmark, France, Germany,
Greece, The Netherlands, Poland, Spain and Sweden)
were randomised in a 1 : 1 ratio to deliver either
usual care following screening or a CHD risk evalua-
tion and communication programme.
A cluster-randomised design was selected in order
that physicians were not required to administer both
usual care and the intervention, as physician educa-
tion during the intervention programme may have
inﬂuenced their approach to usual care. Cluster ran-
domisation was performed by randomly selecting
pairs of study sites within each block of 10 sites using
a computer-based algorithm, and randomly assigning
them to the intervention or usual care arm. At each
site physicians screened patients from an alphabetical
list of potential study participants, taken from the
physicians’ ﬁles, to identify 100 patients who met ini-
tial criteria. Using a random permutation of 100
numbers, patients were then sequentially screened
and consented until 10–15 patients had been enrolled
per site. All study sites were required to adhere to
Good Clinical Practice⁄International Conference on
Harmonization guidelines, and the study protocol
was reviewed and approved by the relevant ethics
committee in each participating country.
Inclusion⁄exclusion criteria
Patients had to be 45–64 years of age with a history
of hypertension, systolic blood pressure ‡ 140 mmHg
(or ‡ 130 mmHg for patients with renal disease)
(39,40), and a 10-year risk of myocardial infarction
(MI) or death because of CHD of ‡ 10% as pre-
dicted by the Framingham equation (41). Exclusion
criteria included a history of CHD or diabetes mell-
itus, or a fasting plasma glucose > 6.9 mmol⁄l
(124 mg⁄dl) at screening. Physicians were required
to be certiﬁed General Practitioners or Internists
who were not using CHD risk algorithms in their
routine practice prior to the study.
Programmes
In both the usual care and intervention groups,
screening was conducted by recording patients’ char-
acteristics and risk factors using a small, portable,
touch-screen computer [Touch Outcomes Collector
(TOC); ASSIST Technologies, Scottsdale, AZ]. The
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calculated the Framingham risk, which was the basis
for inclusion in the study.
In the usual care group, physicians were provided
with the study protocol, which included an explana-
tion of the purpose of the trial, and received training
on the use of the TOC. Predicted Framingham 10-
year risk of CHD was calculated but was not com-
municated to either the physician or patient until the
ﬁnal visit, when the patient’s risk at baseline and at
month 6 was reviewed with the patient by the physi-
cian (although for ethical reasons, laboratory results
used to assess risk were available to the physician
during the study period), and physicians were
instructed locally to provide usual care only during
the study period (Figure 1).
In the intervention group, physicians received
training in risk assessment and communication as
part of an investigator meeting prior to enrolling
patients (usual care physicians were not invited to
participate). At weeks 1–2, physicians were informed
of patients’ predicted CHD risk and were instructed
to advise the patient according to a CHD risk evalu-
ation and communication programme (Figure 1).
This was designed to inform patients of their pre-
dicted absolute and potentially modiﬁable 10-year
risk of CHD (excluding the impact of age and sex on
predicted risk), and to educate them about modiﬁ-
able risk factors and their control through behavio-
ural changes and drug therapy. As part of the
intervention, patients received a Heart Health Report
(38) (Figure S1) generated by the TOC and based on
the patient’s risk factor proﬁle, which was reviewed
with the physician at the same visit (Figure 1). The
report illustrated modiﬁable risk with a bar chart
comparing the patient’s predicted absolute risk with
that of a non-smoker of the same age and sex with
‘normal’ untreated blood pressure (deﬁned in this
study as systolic blood pressure = 139 mmHg) and
cholesterol levels [total cholesterol = 4.9 mmol⁄l
(189 mg⁄dl); high-density lipoprotein cholesterol
(HDL-C) = 1.0 mmol⁄l (40 mg⁄dl) for males or
1.2 mmol⁄l (46 mg⁄dl) for females] (38).
The intervention also involved three follow-up
phone calls by a physician or study nurse at weeks 6,
12 and 18, and patients completed a ‘Knowledge,
Attitudes and Behaviour’ (KAB) questionnaire at
week 0 and week 22–23 (designed speciﬁcally for the
purposes of this trial) (Figure 1). Responses to 3–5
multiple-choice questions within each domain of the
KAB questionnaire were summed, with possible
scores in the range of 0–5 for knowledge, 5–25 for
attitudes and 3–15 for behaviour; higher scores indi-
cating more positive responses. A fourth domain was
included with multiple-choice questions designed to
assess patient satisfaction with the intervention and
physician compliance with the protocol. The Heart
Health Report and KAB questionnaire have been
described in more detail previously (38).
In both the usual care and intervention groups, all
medications (including cardiovascular medications)
were prescribed at the discretion of the physician.
Efﬁcacy measures
Primary efﬁcacy measure
The primary efﬁcacy measure was the Framingham
10-year predicted risk of MI or CHD death at month
6 in the intervention group vs. the usual care group.
Calculation of 10-year predicted risk of CHD was
based on the Framingham model employed in the
NCEP ATP III risk assessment tool (41); variables
Figure 1 Study ﬂow diagram. KAB, Knowledge, Attitudes and Behaviour; TOC, Touch Outcomes Collector; CV, cardiovascular
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lesterol, HDL-C, antihypertensive treatment status
and smoking status.
Secondary efﬁcacy measures
To assess the intervention’s ability to reduce excess
risk attributable to modiﬁable risk factors, the differ-
ence in ‘modiﬁable risk’ was compared between the
intervention and usual care groups. Modiﬁable risk
was deﬁned as a patient’s predicted 10-year risk in
excess of the risk for a ‘normal’ individual, deﬁned as
a non-smoker of the same age and sex, not receiving
antihypertensive treatment, and with normal choles-
terol and blood pressure (as deﬁned above for the
TOC). This was calculated as [(r1)r2)⁄r2] · 100%,
where r1 is the risk for the patient, and r2 is the risk
for the normal individual. Therefore, a patient with
twice the predicted risk of a normal individual would
have a modiﬁable risk of 100%. As the parameters
used to deﬁne r2 were values below which risk could
be further reduced with intensive treatment (42–50),
our deﬁnition of r2 and thus our deﬁnition of modi-
ﬁable risk were conservative.
Additional secondary measures included changes
in blood pressure and lipids, attainment of blood
pressure (< 140⁄90 mmHg) and low-density lipopro-
tein cholesterol [LDL-C; < 3.4 mmol⁄l (130 mg⁄dl)]
goals (20,39,40), weight loss, and changes in smoking
status. Adverse events (AEs) were also monitored.
Statistical analyses
The study was designed to enrol a total of 110 sites
each with 11 evaluable patients, to provide at least
80% power to detect a 10% relative difference in the
primary end-point of Framingham 10-year risk at
month 6 at a 5% signiﬁcance level. Standard devia-
tion of the primary end-point was assumed to be
0.35 (on the natural logarithm scale).
Given the cluster-randomised design, the intra-
class correlation (ICC) of patients from the same site
was considered, where an ICC of 0.05 was used in
the calculation. This sample size was estimated using
two Stata (version 8.2; College Station, TX, USA)
programs: sampsi and sampclus, and conﬁrmed
using statistical simulation methods.
The primary end-point of the Framingham 10-year
predicted risk of CHD at month 6 was evaluated using
a mixed effects model (SAS
  MIXED procedure; SAS
Institute, Cary, NC, USA). As the distribution of the
Framingham risk score is often highly skewed, the
natural logarithm of the primary efﬁcacy end-point
was used as the response variable, with the study
group, country, gender, age and a logarithm of the
10-year predicted Framingham risk at baseline as
covariate terms in the model.
The primary analysis was the calculation of a two-
sided p-value, and the 95% conﬁdence interval, for
the difference between least squares mean values for
the intervention and usual care groups at month 6.
Results
Patient population
Overall, 101 study sites were randomised to deliver
usual care or the risk evaluation and communication
programme. Of these, one site in the intervention
arm was excluded because of not returning the
appropriate local approval documentation. From the
100 sites included in the analysis (50 in each group),
1103 patients were recruited; 1076 completed the
study and 985 were eligible for inclusion in the pri-
mary efﬁcacy analysis (461 allocated to usual care;
524 patients allocated to intervention) (Figure 2). Of
the 118 patients excluded from the efﬁcacy analysis,
for 91 patients this was due to failure of the TOC to
capture the data correctly; 26 patients discontinued
from the study and one patient was ongoing at cut-
off (Figure 2). The estimated sample size of 1210
patients was not met; however, as the observed drop-
out rate was lower than predicted, the study
remained adequately powered.
Among the overall study population, mean age
was 57 years and approximately 14% of patients were
female. On average, patients were overweight (mean
body mass index was 29 kg⁄m
2), and over half were
smokers. While 18% had a history of dyslipidaemia
according to patients’ medical records, 51% were
retrospectively classiﬁed with dyslipidaemia based on
their lipids and medications at screening. Only 3%
had a prior history of non-CHD cardiac disorders
(Table 1).
For patients included in the efﬁcacy analysis, at
the beginning of the study, 82.4% of usual care
patients were receiving cardiovascular medications;
80.9% were receiving antihypertensives and 23.9%
were on serum lipid-reducing medications. Among
intervention patients, 81.5%, 77.9% and 27.1% were
taking cardiovascular medications, antihypertensives
and serum lipid-reducing agents, respectively (Table
3). More than half of patients in both groups were
receiving agents acting on the renin–angiotensin
system at screening.
Predicted 10-year risk of non-fatal MI or CHD
death
After 6 months, the mean (SE) predicted 10-year
risk of non-fatal MI or fatal CHD was reduced
from baseline [16.9% (0.26) in the usual care
group; 17.2% (0.25) in the intervention group], to
13.7% (0.27) and 12.5% (0.25) among usual care
Novel programme to evaluate⁄communicate predicted CHD risk 1487
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This corresponds to a relative decrease in predicted
risk of 18.2% in the usual care group, compared
with 25.7% among patients receiving the interven-
tion.
Following adjustments for baseline risk and other
covariates (including country, age, gender and base-
line risk), predicted absolute 10-year risk of CHD at
month 6 in the intervention group was 0.896 times
that in the usual care group (95% CI: 0.84–0.96;
p = 0.001) (Table 2). The mean change in predicted
absolute risk for the intervention vs. usual care was
)6.3 in the intervention group and )4.9 in the usual
care group, corresponding to a between-group differ-
ence of )1.4 (95% CI: )2.1 to )0.8; p < 0.001;
ICC = 0.033).
Figure 2 Patient ﬂow. AEs, adverse events; TOC, Touch Outcomes Collector
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death
The changes in modiﬁable risk of CHD (i.e. the
risk attributable to cardiovascular risk factors that
can be altered by lifestyle changes and⁄or medica-
tion) in the usual care and intervention groups are
given in Table 2. At baseline, patients in the usual
care and intervention groups had a modiﬁable
CHD risk of 221% and 192%, respectively (i.e. on
average their predicted risk was approximately
three times that of a non-smoker of the same age
and sex with normal untreated blood pressure and
Table 1 Baseline characteristics
Characteristics
Usual care
(n = 538)
Intervention
(n = 565)
Total
(n = 1103)
Female, n (%) 83 (15.4) 71 (12.6) 154 (14.0)
Age (years), mean (SD) 56.9 (4.9) 56.8 (5.1) 56.8 (5.1)
White*, n (%) 534 (99.3) 525 (92.9) 1059 (96.0)
Weight (kg), mean (SD) 87.8 (15.6) 87.8 (15.0) 87.8 (15.3)
Height (cm), mean (SD) 173.2 (8.6) 173.3 (8.5) 173.2 (8.5)
BMI (kg⁄m
2), mean (SD) 29.2 (4.6) 29.2 (4.5) 29.2 (4.5)
SBP (mmHg), mean (SD) 158.6 (14.0) 157.0 (14.0) 157.8 (14.0)
DBP (mmHg), mean (SD) 94.0 (9.7) 93.3 (8.4) 93.6 (9.1)
Total cholesterol (mmol⁄l), mean (SD) 5.9 (1.0) 5.9 (1.0) 5.9 (1.0)
LDL-C (mmol⁄l), mean (SD) 3.9 (1.0) 3.9 (0.9) 3.9 (0.9)
HDL-C (mmol⁄l), mean (SD) 1.4 (0.4) 1.4 (0.4) 1.4 (0.4)
Triglycerides (mmol⁄l), mean (SD) 2.1 (1.3) 2.1 (1.2) 2.1 (1.3)
History of dyslipidaemia, n (%) 93 (17.3) 101 (17.9) 194 (17.6)
Dyslipidaemia according to lipids⁄medication use, n (%) 267 (49.6) 300 (53.1) 567 (51.4)
Smoker, n (%) 257 (55.7) 273 (52.1) 530 (53.8)
History of non-CHD cardiac disorders, n (%) 19 (3.5) 15 (2.7) 34 (3.1)
10-year predicted risk of CHD*, mean (SE) 16.9 (0.26) 17.2 (0.25) 17.1 (0.17)
*p < 0.01. Data are for the efﬁcacy analysis population only (n = 461 usual care; 524 intervention). The most common cardiac
disorder in both groups was arrhythmia (1.6% intervention and 3.0% usual care). To convert mmol⁄lt om g⁄dl divide by 0.02586 for
total cholesterol, LDL-C and HDL-C values, and by 0.01129 for triglycerides. SD, standard deviation; SBP, systolic blood pressure; DBP,
diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; CHD, coronary heart
disease.
Table 2 Change in absolute and modiﬁable Framingham 10-year risk of CHD
Usual care
(N = 461)
Intervention
(N = 524)
Absolute Framingham risk
Baseline, mean (SE) 16.9 (0.26) 17.2 (0.25)
Month 6, mean (SE) 13.7 (0.27) 12.5 (0.25)
Adjusted change in risk from baseline
to month 6, LS mean (95% CI)**
)4.9§ ()5.5 to )4.3) )6.3§ ()6.9 to )5.7)
Modiﬁable Framingham risk (% above ‘normal’)
Baseline, mean (SE) 221 (15.7) 192 (12.4)
Month 6, mean (SE) 117 (9.3) 87 (7.8)
Adjusted change in risk from baseline to
month 6, LS mean (95% CI)*
)96§ ()115 to )78) )115§ ()133 to )97)
*p < 0.05. **p < 0.001, for intervention vs. usual care. §p < 0.001 vs. baseline. Data were adjusted for baseline risk and other
covariates. Deﬁned as the risk for a non-smoker of the same age, gender, not receiving antihypertensive treatment and with total
cholesterol = 4.9 mmol⁄l (189 mg⁄dl), high-density lipoprotein cholesterol = 1.0 mmol⁄l (40 mg⁄dl) for males or 1.2 mmol⁄l
(46 mg⁄dl) for females = 1.3 mmol⁄l (50 mg⁄dl), and systolic blood pressure = 139 mmHg (38). SE, standard error; LS, least square;
CI, conﬁdence interval.
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substantially lowered in both groups but was still
117% in the usual care group, vs. 87% in the
intervention group. After adjusting for baseline risk
and other covariates, the mean absolute difference
in the change in modiﬁable risk with the interven-
tion vs. usual care was )18.5% (95% CI: )35.5 to
)1.4; p = 0.034) (Table 2).
Changes in modiﬁable risk factors and weight
loss
Over the 6 month study period, mean blood pressure
was reduced from 159⁄94 to 144⁄87 mmHg in the
usual care group, and from 157⁄93 to 138⁄85 mmHg
in the intervention group. After adjusting for baseline
values and other covariates, blood pressure was
reduced signiﬁcantly more among patients receiving
the intervention than among those receiving usual care
(p < 0.01) (Figure 3A).
Baseline LDL-C was approximately 3.9 mmol⁄l
(150 mg⁄dl) in both groups, which was reduced to
3.5 mmol⁄l (135 mg⁄dl) and 3.4 mmol⁄l
(131 mg⁄dl) in the usual care and intervention
groups respectively, after 6 months. After adjust-
ments, a slightly greater decrease in LDL-C was
observed in the intervention group than with usual
care, although the difference between groups was not
signiﬁcant (p = 0.052) (Figure 3B). Similarly, total
cholesterol was reduced from approximately
5.9 mmol⁄l (228 mg⁄dl) in both groups to
5.6 mmol⁄l (216 mg⁄dl) in the usual care group
compared with 5.4 mmol⁄l (211 mg⁄dl) in the
intervention group; the between-group difference
for these reductions was not signiﬁcant (p = 0.095)
A B
CD
Figure 3 Changes in modiﬁable risk factors. (A) Change in blood pressure. (B) Change in lipids. (C) Attainment of blood pressure and LDL-C
goals. (D) Change in smoking status. **p < 0.0001 vs. baseline.
At baseline, 28.9% and 29.8% of patients in the usual care and intervention groups
respectively, were at LDL-C goal; < 1% of patients were at blood pressure goal at baseline. BP, blood pressure; LS, least square; CI, conﬁdence
interval; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol
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non-signiﬁcant increase in triglycerides of 3.7%
(95% CI: )2.8 to 10.3; p = 0.26) in the usual care
group, and 3.2% (95% CI: )3.1 to 9.4; p = 0.32) in
the intervention group (p = 0.88 between groups).
Overall, a signiﬁcantly higher proportion of
patients in the intervention group achieved blood
pressure and LDL-C goals than in the usual care
group (Figure 3C). Patients in the intervention group
were 1.9 times (95% CI: 1.2 to 2.9; p = 0.003) as
likely to attain their blood pressure goal; 1.6 times
(95% CI: 1.2 to 2.2; p = 0.005) as likely to attain
LDL-C goal and 2.1 times (95% CI: 1.3 to 3.3;
p = 0.002) as likely to attain both goals as patients
in the usual care group.
Within the intervention group, 97% of smokers
were encouraged to stop smoking by the physician
(6.3% of all patients were prescribed anti-smoking
medications). Among these patients, 29.3% were
reported to have quit smoking at the end of the
study, compared with 21.4% of smokers in the usual
care group (p = 0.04) (Figure 3D).
Across both treatment groups, reductions in pre-
dicted modiﬁable risk (Table 2) were driven predom-
inantly by decreases in systolic blood pressure
(accounting for 25.5% of the risk reduction), fol-
lowed by changes in total cholesterol (21.6% of the
risk reduction), and quitting smoking (15.7% of the
risk reduction), while only 7.8% of the modiﬁable
risk reduction was due to increases in HDL-C (per-
centages are based on analysis of variance compo-
nents from a regression model; the difference from
the sum of percentages to 100% is the remainder of
the variability unexplained by the model).
Within the intervention group, after adjusting for
covariates at baseline, patients achieved a mean
decrease in weight of 1.14 kg (95% CI: 1.71 to 0.56),
which although marginal, was statistically signiﬁ-
cantly greater than the mean change in weight
among usual care patients [)0.35 kg (95% CI: )0.95
to 0.25); p = 0.015].
Patient responses to KAB questionnaire
At month 6, among patients in the intervention
group, mean scores increased by 7%, 5% and 12%,
from baseline values of 4.4, 21.8 and 11.6
(p < 0.0001 from baseline for all) for the knowledge,
attitudes, and behaviour domains of the question-
naire, respectively. Increased scores for attitudes
correlated signiﬁcantly (p = 0.014) with reductions
in modiﬁable Framingham risk, while knowledge and
behaviour scores showed no signiﬁcant correlation
with modiﬁable risk reduction. In addition, scores
for attitudes and behaviour, but not knowledge, cor-
related signiﬁcantly (p < 0.0001 and p = 0.0048)
with decreases in blood pressure. None of the scores
correlated with lipid changes. Over three-quarters of
patients (77.5%) reported that their physician spent
> 5 min explaining the Heart Health Report. When
asked their favourite part of the intervention in
Table 3 Percentage of patients receiving medications at screening and at the end of the study
Patients receiving
medications, n (%)
Usual care (N = 461) Intervention (N = 524)
Screening
Final
visit
%
Change Screening
Final
visit
%
Change
Any cardiovascular medications 82.4 93.3 13.2 81.5 89.1 9.4
Any antihypertensive 80.9 91.1 12.6 77.9 84.7 8.8
ACE inhibitors 29.3 33.0 12.6 22.0 27.3 24.3
ACE inhibitor combinations 5.0 6.5 30.4 4.8 5.9 24.0
ARBs 14.3 17.4 21.2 14.1 16.0 13.5
ARB combinations 8.5 10.6 25.6 10.9 13.4 22.8
Beta-blocking agents 37.1 41.2 11.1 29.4 31.3 6.5
CCBs 22.1 27.3 23.5 23.9 28.8 20.8
Diuretics 28.0 32.5 16.3 15.3 20.2 32.5
Other antihypertensives 6.5 6.7 3.3 5.0 6.7 34.6
Serum lipid-reducing agents 23.9 38.8 62.7 27.1 42.0 54.9
Aspirin 4.1 5.2 26.3 8.2 10.9 32.6
Peripheral vasodilators 3.0 3.5 14.3 1.5 1.5 0
Anti-obesity medications 0 0 0 0.4 0.4 0
Others* 2.4 4.1 72.7 2.7 4.0 50.0
*Including antihaemorrhoidals for topical use, corticosteroids and ﬂavonoids. ACE, angiotensin-converting enzyme; ARB, angiotensin
receptor blocker; CCB, calcium channel blocker.
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said the additional time with their doctor, 14.5% the
personal report, 4.0% the follow-up calls and a fur-
ther 30.9% enjoyed all three equally (16.0% did not
answer this question and 2.7% responded ‘none of
the above’).
Change in medications from screening
to the end of the study
Over the study period, cardiovascular medications
were prescribed to 93% of patients in the usual care
group and 90% of patients randomised to the inter-
vention. Overall, the use of cardiovascular medica-
tions increased from screening to the end of the
study in both groups. From screening to month 6,
the percentage of patients prescribed cardiovascular
medications increased from 82.4% to 93.3% in the
usual care group, and from 81.5% to 89.1% in the
intervention group (p < 0.0001 for the increase in
medication use from screening in both groups;
p = 0.059 between groups). The percentage of
patients receiving antihypertensives increased from
80.9% to 91.1%, and 77.9% to 84.7%, among usual
care and intervention patients respectively, and the
use of serum lipid-reducing agents from 23.9% to
38.8%, and 27.1% to 42.0% respectively (Table 3).
Adverse events
A total of 34 patients, including two usual care
patients who died (causes of death were cardiac
arrest and sudden death), experienced 38 serious
AEs (SAEs). The most common SAEs were cardiac
disorders, including MI (three patients), cardiac
arrest (one patient), coronary artery disease (one
patient), myocardial ischaemia (one patient) and
tachycardia (one patient). AEs reported by ‡ 1% of
patients in the usual care or intervention group are
listed in Table 4. The percentage of patients who dis-
continued from the study was 2.8% in the usual care
group and 1.9% in the intervention group. The most
common reason for discontinuation in both groups
was that the patient defaulted (2.0% and 1.4% in
the usual care and intervention groups respectively)
(Figure 2).
Discussion
The REACH OUT study demonstrated that a CHD
risk evaluation and communication programme
mediates a statistically signiﬁcant reduction in
predicted Framingham cardiovascular risk when
compared with usual care, among patients with
hypertension and moderate cardiovascular risk. At
the end of the 6-month study period, patients
receiving the intervention had an approximately
10% lower relative predicted 10-year risk of CHD
compared with patients given usual care only. Fur-
thermore, patients in the intervention group were
observed to have a signiﬁcantly lower modiﬁable
risk (which excludes the effects of age and gender
on predicted CHD risk), relative to those receiving
usual care.
Improvements in risk factor management with
intervention vs. usual care
At 6 months, statistically signiﬁcant differences were
observed between the intervention and usual care
groups for blood pressure decreases and smoking
cessation. Indeed, approximately 8% more patients
in the intervention group were reported to have quit
smoking during the study than in the usual care
group. Reductions in total cholesterol were also
numerically greater with the intervention than with
usual care, although differences between groups did
not reach statistical signiﬁcance. Framingham risk
reductions driven by changes in these factors were
impressive in both groups [18% relative reduction
with usual care (adjusted absolute reduction 4.9
percentage points); 26% with intervention (adjusted
absolute reduction 6.3 percentage points)], particu-
larly given that the majority of patients were already
receiving cardiovascular medications at screening.
Additionally, improvements in factors such as LDL-C
and weight loss, while not reﬂected in the Framing-
ham risk estimates, nonetheless contribute to a
positive change in patients’ overall risk proﬁles.
Importantly, approximately twice as many patients in
the intervention group achieved blood pressure and
LDL-C goals compared with usual care, implying an
improvement in the treatment of these risk
factors towards guideline-recommended targets by
physicians.
While it is not possible to determine precisely the
causes of improved CHD risk reduction mediated by
Table 4 Adverse events reported by ‡ 1% of patients in
the usual care or intervention group
Adverse event
n (%)
Usual care
(N = 538)
Intervention
(N = 565)
Back pain 21 (3.9) 16 (2.8)
Headache 10 (1.9) 12 (2.1)
Cough 6 (1.1) 10 (1.8)
Upper respiratory
tract infection
3 (0.6) 8 (1.4)
Osteoarthritis 6 (1.1) 8 (1.4)
Pharyngitis 12 (2.2) 7 (1.2)
Abdominal pain 2 (0.4) 6 (1.1)
Bronchitis 18 (3.3) 6 (1.1)
Dyslipidaemia 8 (1.5) 6 (1.1)
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are likely attributable to behaviour modiﬁcations
among both physicians and patients. The prescrip-
tion of cardiovascular medications increased in both
the intervention and usual care groups over the
study period, which likely contributed to observed
risk reductions, although overall increases in the use
of cardiovascular medications were slightly lower in
the intervention group than in the usual care group.
Nonetheless, knowledge of patients’ risk status may
have prompted physicians to prescribe higher doses
of medications or more appropriate therapies. Data
for these variables were not collected, however, so
ﬁrm conclusions cannot be drawn.
Greater interaction with their physician, and
increased knowledge and understanding of their risk
status, may have motivated patients to adhere to a
more healthy diet, increase their exercise, quit smok-
ing or maintain better adherence with medications.
The results of the KAB questionnaire demonstrated
that patients did indeed experience a small, but sta-
tistically signiﬁcant, increase in their scores for
knowledge, attitudes and behaviour, which may have
contributed to the observed improvements in CHD
risk reduction. Of interest was the ﬁnding that
patient attitudes appeared to have the greatest corre-
lation with predicted risk, indicating the importance
of positively inﬂuencing a patient’s attitudes to drug
therapy and lifestyle changes. In addition, the Heart
Health Report was designed to motivate patients by
prompting them to consider their future life goals
(e.g. their child’s wedding, retirement, the birth of a
grandchild or travelling the world), which may be a
further factor in promoting positive lifestyle changes
(38). However, only limited data were collected to
evaluate these factors, precluding a full assessment of
the causal mechanisms.
Despite the beneﬁts of the intervention on
patients’ risk factor proﬁles, the degree of risk reduc-
tion in the usual care group was also remarkable.
This may be attributed in part to physicians altering
their treatment strategies as a result of measuring
variables such as blood pressure and lipids during
screening procedures, realisation that patients’ risk
was ‡ 10% (required for inclusion), or because of
their awareness of the purpose of the study to evalu-
ate the beneﬁts of overall cardiovascular risk assess-
ment. Furthermore, because of their involvement in
a clinical trial, and knowledge that their treatment
patterns and achieved risk factor reductions were
observed as part of the trial protocol, physicians may
have dedicated more time to patient consultations
than in their usual clinical practice. These hypotheses
are supported by observed increases in the prescrip-
tion of cardiovascular medications, which were
slightly greater in the usual care arm than in the
intervention arm. Similarly, patients may have expe-
rienced an increase in their motivation to adhere to
drug therapy and lifestyle changes because of their
involvement in a clinical trial. It is therefore possible
that the REACH OUT intervention programme may
mediate greater incremental beneﬁts in clinical prac-
tice, when compared with true ‘usual care’ outside of
a clinical trial setting.
Modiﬁable risk assessment
We believe that the assessment of modiﬁable risk as
well as absolute risk is an important clinical concept,
which may allow physicians to evaluate more clearly
the potential risk reductions that can be achieved
with optimal risk factor management. However, it
should be noted that estimations of modiﬁable risk
are dependent upon the accepted deﬁnition of a
‘normal’ individual. In this study, normal levels of
blood pressure and lipids were deﬁned as a systolic
blood pressure of 139 mmHg, total cholesterol of
4.9 mmol⁄l (189 mg⁄dl) and HDL-C of 1.0 mmol⁄l
(40 mg⁄dl) for males or 1.2 mmol⁄l (46 mg⁄dl) for
females (38), which were considered to be levels
achievable with the medications readily available in
clinical practice. However, clinical outcomes studies
have demonstrated beneﬁts of reducing cholesterol to
lower levels, particularly among high-risk patients or
those with prior CHD (42–44), and observations
from subanalyses and epidemiological studies suggest
that reducing blood pressure to lower levels may
have similar beneﬁts (45–50). In addition, the nor-
mal individual for the purposes of this study was
deﬁned as not receiving antihypertensive treatment.
Thus, in the calculation of modiﬁable risk, a previ-
ously untreated patient would have an increase in
their modiﬁable risk if given antihypertensive therapy
during the study, unless this was offset by a consid-
erable reduction in systolic blood pressure. The
changes in modiﬁable risk reported in this study are
therefore conservative.
Implications for clinical practice
Several studies have demonstrated that patient edu-
cation and support strategies can help to improve
patient adherence to medications and mediate
improvements in risk factor modiﬁcation in clinical
practice (27–37). These include large trials of nurse-
led interventions such as the recent EuroAction trial
and the Oxford and collaborators health check (OX-
CHECK) studies. In EuroAction (27–29), patients
with high cardiovascular risk receiving a 16-week,
nurse-led cardiovascular prevention and rehabilita-
tion programme experienced signiﬁcant beneﬁts in
terms of risk factor reductions and dietary improve-
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comparable absolute difference in blood pressure and
LDL-C goal attainment between EuroAction and
REACH OUT among high-risk patients receiving the
intervention vs. usual care (58% vs. 41%, respec-
tively, for blood pressure; 45% vs. 35%, respectively,
for LDL-C). In contrast to REACH OUT, more
patients received statins (38% vs. 23%, p = 0.03) and
angiotensin-converting enzyme inhibitors (29% vs.
20%, p = 0.02) in the intervention group than in the
usual care group, which likely contributed to the
beneﬁts observed in EuroAction. In addition, a simi-
lar nurse-led, family-oriented cardiovascular screen-
ing and lifestyle intervention programme in the
earlier British Family Heart Study was associated
with a 12% reduction in predicted coronary risk
(51). In OXCHECK nurses provided regular patient
health checks, which were associated with signiﬁcantly
lower levels of blood pressure ()2.5⁄1.5 mmHg) and
total cholesterol [)0.19 mmol⁄l (7.3 mg⁄dl)] vs. the
control group at 3 years’ follow-up (30). The authors
for the OXCHECK study suggest that these observed
reductions in blood pressure would translate to a
long-term reduction in risk of MI of 7%, and the
decreases in cholesterol to a risk reduction of 6% in
men and 13% in women (30).
However, previous studies speciﬁcally evaluating
the beneﬁts of cardiovascular risk assessment and
communication have demonstrated little or no effect
on predicted CHD risk (24–26). In the recent Car-
diovascular Health Evaluation to improve Compli-
ance and Knowledge among Uninformed Patients
(CHECK-UP) study (24), conducted in Canada
among patients with previously untreated dyslipida-
emia, physicians and patients were informed of the
patient’s calculated risk through a one-page printout,
and patients received ongoing feedback regarding the
change in their risk and reductions in ‘cardiovascular
age’ (deﬁned as the patient’s age minus the difference
between their estimated remaining life expectancy
and the average remaining life expectancy for Cana-
dian individuals of the same age and sex) as a result
of lifestyle changes or drug treatment. The CHECK-
UP study demonstrated a statistically signiﬁcant
reduction in 10-year Framingham risk of CVD (for
patients without CVD) with the intervention vs.
usual care; however, the between-group difference
was only approximately )0.6 percentage points ()5.9
with intervention vs. )5.3 with usual care), or about
half as effective as the REACH OUT intervention
()1.4 percentage points). Although the REACH OUT
study design and patient population are not directly
comparable with these earlier studies (24–26), the
favourable results observed with the risk evaluation
and communication programme may be an indica-
tion of the effectiveness of the Heart Health Report
for communicating CHD risk, and⁄or the beneﬁts of
the additional follow-up calls from the physician or
study nurse.
Elements of the intervention in REACH OUT that
focus on increased communication between provid-
ers and patients could potentially be provided not
only by physicians but also by nursing staff, pharma-
cists or other healthcare workers, and incorporated
relatively easily into routine clinical practice. How-
ever, in order to achieve greater improvements in
modiﬁable risk factors than those achieved by patient
education⁄counselling alone (30,34,36,52), it may be
beneﬁcial to consider additional interventions as part
of a multifactorial approach, for example, adherence
interventions (32,35), or CHD risk evaluation as in
REACH OUT. In contrast to large-scale interventions
such as that in the EuroAction study (27–29) that, if
implemented in clinical practice, would require the
hiring of additional nursing staff and the associated
costs, the REACH OUT intervention could poten-
tially be provided by existing healthcare workers,
with only the costs related to the small increase in
time devoted to each patient. However, a direct com-
parison of various investments of clinician’s time
would be required to fully understand the value of
the REACH OUT intervention compared with alter-
natives. We have no measurement of the exact time
that the physician or nurse spent with the patient in
REACH OUT (although 78% of patients reported
that the physician spent more than 5 min explaining
the report), which would be an important factor in
determining the cost-effectiveness of the interven-
tion.
Despite the reductions in risk achieved, at the end
of the study patients’ modiﬁable risk in both the
intervention and usual care groups remained approx-
imately twice as high as for an individual with nor-
mal blood pressure and lipids, indicating that
additional beneﬁt could be gained from further
reductions in modiﬁable risk factors. Notably, overall
levels of blood pressure and LDL-C goal attainment
observed in REACH OUT were good when com-
pared with those in usual clinical practice (9,10), but
were lower than those achieved in recent clinical tri-
als of antihypertensive and lipid-lowering therapies
among patients at varying levels of cardiovascular
risk (53–55). In particular, reductions in lipid levels
were smaller in REACH OUT than in these other tri-
als, contributing to markedly lower levels of LDL-C
goal attainment (53–55). Similarly, the achieved
reductions in Framingham risk were smaller than
those demonstrated in recent studies evaluating con-
comitant blood pressure and lipid-lowering therapy
(54,56). This may be due to above-average levels of
1494 Novel programme to evaluate⁄communicate predicted CHD risk
ª 2008 The Authors
Journal compilation ª 2008 Blackwell Publishing Ltd Int J Clin Pract, October 2008, 62, 10, 1484–1498adherence to allocated study medications in these tri-
als, but also suggests that the treatment strategies
employed by physicians in REACH OUT and in clin-
ical practice could be improved, perhaps with the
use of newer treatments, greater uptitration of medi-
cations or the addition of statin therapy in patients
with hypertension and additional risk factors (6).
Interventions with the potential to improve patient
adherence, for instance the use of single-pill combi-
nation therapies or blister packs to improve conve-
nience of dosing (32,35,57,58), could provide further
beneﬁts to improve risk factor control (59–62).
Limitations and additional considerations
Concerns were raised by the Ethics Committee in
Norway that informing patients of their cardiovascu-
lar risk may generate unnecessary anxiety, and the
Norwegian committee did not approve the REACH
OUT protocol on these grounds. In addition, during
the screening process, a number of patients were
excluded as they did not wish to be informed of
their cardiovascular risk. However, we believe that
the REACH OUT study helps to conﬁrm that a real-
istic perception of cardiovascular risk can motivate
patients and physicians to improve risk factor con-
trol when combined with a follow-up and support
strategy. This concept is supported by a study by
Troein et al. (63), which indicated that providing
supportive information on cardiovascular risk factors
does not increase patient anxiety. Nonetheless, this
issue is worthy of consideration and risk communi-
cation should be addressed sensitively.
The Framingham calculation was chosen as the
method of risk estimation used in REACH OUT as
this model is a well understood and effective tool to
summarise multiple risk factors and global cardiovas-
cular risk (21,41). It is a limitation of this study,
however, that the Framingham model has not been
validated broadly in European populations and has
been reported to overestimate absolute CHD risk in
some studies of European patients (64,65). Further-
more, risk algorithms are not validated for the
assessment of treatment effects. Short-term reduc-
tions in risk factors leading to reduced estimates of
Framingham risk will not necessarily eliminate asso-
ciated accumulated risks; patients need to maintain
these improvements over the long term to reduce
their actual risk of disease, and it is uncertain
whether the accumulated effects of long-term eleva-
tions in risk factors are entirely reversible even with
prolonged therapeutic control. In addition, daily bio-
logical variations in blood pressure and lipid mea-
surements can affect the precision of risk estimations
(66). Risk algorithms can only provide an estimation
of long-term risk, and no one method for risk pre-
diction is perfect (67). However, as these limiting
factors will be equal in both treatment arms, the
between-group differences are still meaningful and
we believe that relative changes in predicted risk fol-
lowing intervention can provide a useful indication
of the potential beneﬁts if improvements are main-
tained. In order to accurately determine the true
effect of our intervention on cardiovascular out-
comes, long-term follow-up studies of patient cardio-
vascular events are required.
Few women met the REACH OUT study inclusion
criterion of 10-year absolute risk ‡ 10%, and those
who were included had a high modiﬁable risk com-
pared with the male population. Thus, the ﬁndings
from REACH OUT may need to be veriﬁed among a
greater sample of female patients. Similarly, our ﬁnd-
ings do not necessarily extend to patients with a his-
tory of CHD or diabetes, patients with predicted risk
scores < 10% or those who are ‡ 65 years of age, as
all of these groups were excluded from the study. An
additional study limitation is the relatively short fol-
low-up period of 6 months, which precludes infer-
ences about the long-term impact of the intervention
on sustaining improvements in modiﬁable risk fac-
tors and cardiovascular risk reduction.
Conclusions
The REACH OUT study demonstrates that a patient-
focused, physician-implemented CHD risk evaluation
and communication programme can effectively lower
predicted CHD risk compared with usual care among
patients with hypertension and elevated cardiovascu-
lar risk, through improvements in modiﬁable risk fac-
tors. This strategy for achieving beneﬁts in risk
reduction without dictating drug therapy has wide
applicability and is of public health importance. These
data support the role of global CHD risk assessment,
risk communication and risk factor education for
CHD prevention in a multinational, primary care set-
ting. By combining this risk evaluation and communi-
cation strategy with more intensive treatment to
reduce residual modiﬁable cardiovascular risk, we
believe that substantial improvements in CVD pre-
vention could be achieved in clinical practice.
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